Articles On Paradigm Biopharmaceuticals (ASX:PAR)
Title | Source | Codes | Date |
---|---|---|---|
Why Energy Resources, Paradigm, Piedmont Lithum, and Seek shares are dropping today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and slipped into the red. At the time of writing, the benchmark index is down slightly to 7,221.3 points. Four ASX shares that are falling more tha... |
Motley Fool | PAR | 1 year ago |
ASX Health Stocks: Paradigm shows good Phase 2 results, Race Oncology jumps 8pc after third party report on Zantrene
Paradigm Biopharma demonstrates efficacy of knee osteoarthritis drug Race Oncology released a third-party report showing the potential for Zantrene Emyria and Aspen Australia have signed an exclusive binding deal Paradigm Biopharmaceuti... |
Stockhead | PAR | 1 year ago |
CLOSING BELL: ASX closes higher to end week, materials leading bourse upwards
ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So... |
Stockhead | PAR | 1 year ago |
Why Appen, Core Lithium, Paradigm, and Sayona Mining shares are racing higher
The S&P/ASX 200 Index (ASX: XJO) is on course to end the week (and year) in a positive fashion. In afternoon trade, the benchmark index is up 0.55% to 7,057.8 points. Four ASX shares that are climbing more than most today are listed b... |
Motley Fool | PAR | 1 year ago |
Paradigm Biopharmaceuticals (ASX:PAR) receives notice of allowance for US patent
Paradigm Biopharmaceuticals (PAR) receives a notice of allowance from the US Patent and Trademark Office (USPTO) The notification demonstrates PAR’s patent application has been examined and satisfies the requirements for patentability The p... |
themarketherald.com.au | PAR | 1 year ago |
Market Highlights: ASX to rise, oil price volatility, and 5 small caps to watch on Wednesday
The ASX is poised to open higher on Wednesday after a rally in New York Oil prices higher as Saudi said OPEC+ wasn’t considering output increase Crypto broker Genesis near bankcruptcy The ASX is set to open higher on Wednesday after a bro... |
Stockhead | PAR | 1 year ago |
Why Best & Less, Cettire, Life360, and Paradigm shares are sinking today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.6% to 7,184.3 points. Four ASX shares that have failed to follow the market higher today a... |
Motley Fool | PAR | 1 year ago |
Why is this ASX All Ords biotech share crashing 12% today?
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day. In afternoon trade, the biotechnology companyâs shares are down 12% to $1.48. This makes the Paradigm share price one of the worst performers on the Al... |
Motley Fool | PAR | 1 year ago |
Paradigm Pharmaceuticals (ASX:PAR) Paul Rennie re-appointed MD as CEO steps down
Paradigm Pharmaceuticals’ (PAR) CEO, Marco Polizzi, has stepped down from his role after just five months with the companyMr Polizzi will exit the role on February 20, 2023, and Paradigm did not say why he was stepping downParadigm has appo... |
themarketherald.com.au | PAR | 1 year ago |
ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams
Bod Australia returns positive results from Phase 1 trial Paradigm and Impedimed make executive changes Creso Pharma no longer the subject of ASIC investigation Cannabis stock Bod Australia (ASX:BOD) announced positive results from its Ph... |
Stockhead | PAR | 1 year ago |
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A... |
Stockhead | PAR | 1 year ago |
Paradigm Biopharmaceuticals (ASX:PAR) doses first UK subject in phase three trial
Paradigm Biopharmaceuticals (PAR) doses its first subject in the United Kingdom as part of its phase three clinical trial for the treatment of knee osteoarthritisThe first patient has been treated with Paradigm’s injectable pentosan polysul... |
themarketherald.com.au | PAR | 1 year ago |
Why Appen, GQG, Paradigm, and Talga shares are tumbling lower
The S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a decline. In afternoon trade, the benchmark index is down 0.6% to 6,774.4 points. Four ASX shares that are falling more than most today are listed below. Here’s why th... |
Motley Fool | PAR | 1 year ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | PAR | 1 year ago |
Paradigm Biopharmaceuticals [ASX:PAR] Spikes in Phase II Trial Results
Drug development company Paradigm Biopharmaceuticals [ASX:PAR] reported positive results for one of its clinical trials focused on osteoarthritis (OA). The post Paradigm Biopharmaceuticals [ASX:PAR] Spikes in Phase II Trial Results appeared... |
MoneyMorning | PAR | 1 year ago |
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial
Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t... |
Stockhead | PAR | 1 year ago |
Why Allkem, Evolution, Paradigm, and Sayona Mining shares are zooming higher
The S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday and racing higher. In afternoon trade, the benchmark index is up 2.5% to 6,619.2 points. Four ASX shares that have climbed more than most today are listed below. Here’s why th... |
Motley Fool | PAR | 1 year ago |
Why is the Paradigm share price rocketing 19% today?
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt in style. In morning trade, the drug development company’s shares are up 19% to $1.50. Why is the Paradigm share price rocketing higher? Investor... |
Motley Fool | PAR | 1 year ago |
Closing Bell: Small caps tip and global markets teeter into the weekend
Small caps slip down 3.3%, and global markets look equally wobbly China’s manufacturing Purchasing Managers’ Index (PMI) actually grew in September Alchemy Resources draws a ballot for some prospective lithium ground near big names in WA... |
Stockhead | PAR | 1 year ago |
CRITERION: Gains without pains? Maybe tackle these sporting injury stocks instead
As nerves mount for players on both NRL Grand Final sides preparing to line up at Staiudm Australia on Sunday night, it’s worth remembering the myriad enterprises that enable sportspeople to leap higher and kick further – while also tending... |
Stockhead | PAR | 1 year ago |
Paradigm Biopharmaceuticals (ASX:PAR) flags successful safety review in MPS-VI trial
Paradigm Biopharmaceutical (PAR) has flagged a successful safety review of a phase two study of its pentosan polysulfate sodium (PPS) product in mucopolysaccharidosis type VI (MPS-VI) patientsThe company says the safety monitoring physician... |
themarketherald.com.au | PAR | 1 year ago |
3 ASX All Ords shares that marched higher on Friday
The S&P/ASX All Ordinaries Index (ASX: XAO) closed in the red on Friday, down 1.9% to just below 6,789 points. But as is often the case, a few ASX All Ords shares defied the index and ramped higher today. Let’s take a look. KMD Brand... |
Motley Fool | PAR | 1 year ago |
Paradigm Biopharmaceuticals (ASX:PAR) raises $66m for clinical trials
Paradigm Biopharmaceuticals (PAR) raises $66 million through a placement and entitlement offer to fund the development of its clinical trialsAdditionally, the money will support business and product development, as well as working capitalTh... |
themarketherald.com.au | PAR | 1 year ago |
Paradigm share price rises despite $39 million loss in FY22
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is enjoying a day in the green today after the company announced its yearly financial results for FY22. Shares in the ASX biotech company are up 2.34% at $1.31 in early afternoon t... |
Motley Fool | PAR | 1 year ago |
Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 7,072.6 points. Four ASX shares that have failed to follow the market higher today ar... |
Motley Fool | PAR | 1 year ago |
Paradigm Biopharmaceuticals (ASX:PAR) taps investors for $66m to fund future developments
Paradigm Biopharmaceuticals (PAR) taps investors for $66 million to fund developments into the 2024 calendar year The fully underwritten capital raise will comprise a $45.7 million institutional placement and a $20.3 million entitlement of... |
themarketherald.com.au | PAR | 1 year ago |
ASX Health Stocks: Mesoblast raise signals potential comeback for biotechs
Recent cap raising suggests biotechs may finally be making a comeback Mesblast annnounced a US$45m cap raise last week Today, Paradigm, Opthea, and Proteomics also announced fund raises Over the past year, the biotech sector has been caug... |
Stockhead | PAR | 1 year ago |
GPT share price lifts despite 30% profit plunge
The GPT Group (ASX: GPT) share price is making a commendable move upwards today following the release of its interim results for 2022. At the time of writing, shares in the diversified property group are 5.7% in the green. As a result, th... |
Motley Fool | PAR | 1 year ago |
Stock market sell-off: How I’m continuing to make passive income
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. I have been entrusted... |
Motley Fool | PAR | 1 year ago |
Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is plummeting after coming out of a trading halt this morning. At the time of writing, the biopharmaceutical companyâs shares are fetching at $1.45, down 26.95%. Whatâs drivi... |
Motley Fool | PAR | 1 year ago |
Your investments vs. a bear market: How to come out on top
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. When the market is do... |
Motley Fool | PAR | 1 year ago |
Closing Bell: Ragusa Metals leaps 60% on lithium love; local markets follow on first glint of inflation hopes
ASX 200 and small caps rise circa 1% Regional markets jump on strong leads, US inflation data Ragusa Metals: up 60% Local markets took off at the open, feeling a little of the excitement which took hold of Wall Street overnight. The bench... |
Stockhead | PAR | 1 year ago |
Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise
Paradigm Biopharmaceuticals (PAR) enters into a trading halt ahead of a capital raise There is currently no details on how much the company is aiming to raise or where it plans to spend the money Under the halt, company shares will be paus... |
themarketherald.com.au | PAR | 1 year ago |
Up 90% in 2 weeks, here’s why the Paradigm share price has been halted
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company requested a trading halt. The Paradigm share price has rocketed from $1.05 per share on 28 July to $1.99 per share at Wednesdayâs close... |
Motley Fool | PAR | 1 year ago |
Paradigm Biopharma in $62m cash call
Listed drug repurposing business Paradigm Biopharmaceuticals has put a big raise to investors, asking them to tip in $62 million while it waits for key trial results. |
AFR | PAR | 1 year ago |
Nickel Industries share price slips on $225 million debt capital raise
The Nickel Industries Ltd (ASX: NIC) share price closed lower on Monday amid a significant debt announcement by the mineral exploration company. Nickel Industries shares finished the day down 1.82% at $1.08 each after hitting an intraday l... |
Motley Fool | PAR | 1 year ago |
Paradigm [ASX:PAR] Spikes on Clinical Program Update
Drug developer Paradigm Biopharmaceuticals [ASX:PAR] rose more than 10% on Monday after releasing an update on its clinical program. The post Paradigm [ASX:PAR] Spikes on Clinical Program Update appeared first on Money Morning Australia. |
MoneyMorning | PAR | 1 year ago |
Here are the 3 most heavily traded ASX 200 shares on Monday
It’s been a slow start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. As it stands today, the ASX 200 has risen by an anaemic 0.07% and is hovering around the 7,020 point mark. So let’s dig a little deeper into t... |
Motley Fool | PAR | 1 year ago |
Why Appen, Imugene, OZ Minerals, and Paradigm shares are charging higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up slightly to 7,017.1 points. Four ASX shares that are climbing more than most today are listed... |
Motley Fool | PAR | 1 year ago |
Now’s the time to play defense if you have retirement on the horizon
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Even with the curren... |
Motley Fool | PAR | 1 year ago |
4 key traits Warren Buffett uses to pick the best stocks
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Warren Buffett has a... |
Motley Fool | PAR | 1 year ago |
Why is the Paradigm Biopharmaceuticals share price up 12% on Monday?
The Paradigm Biopharmaceuticals Limited (ASX: PAR) share price is soaring today amid news the company will present its research at an international conference. Paradigm shares are trading at $1.92 each, up 11.63%, at the time of writing. E... |
Motley Fool | PAR | 1 year ago |
What are you getting when you buy Wesfarmers shares on the ASX today?
Wesfarmers Ltd (ASX: WES) shares are among the most popular ASX blue chip investments on the S&P/ASX 200 Index (ASX: XJO) today. This ASX 200 industrial and retailing conglomerate is now the ninth-largest share on the ASX 200 index by... |
Motley Fool | PAR | 1 year ago |
ASX Health Stocks: Acrux and Lumos await potential approvals from the US FDA
Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,... |
Stockhead | PAR | 1 year ago |
Mayne Pharma share price lifts on FDA approval
The Mayne Pharma Group Ltd (ASX: MYX) share price is up 4.48% on Monday morning amid news the company has received US regulatory approval. Shares of Mayne Pharma are currently trading at 35 cents each after opening at 33.5 cents a share th... |
Motley Fool | PAR | 1 year ago |
The OZ Minerals share price is rocketing 35% after BHP bid
The OZ Minerals Limited (ASX: OZL) share price has shot higher to be the best performer in the S&P/ASX 200 Index (ASX: XJO) at the time of writing. OZ Minerals shares are currently trading for $25.51 each, a 34.83% leap from their prev... |
Motley Fool | PAR | 1 year ago |
Evening Report: 13 July, 2022
ShareCafeEvening Report: 13 July, 2022 by Melissa Darmawan Australian shares lacked conviction as investors remained cautious ahead of the US inflation data. The index remained in a holding pattern as it jumped above and below the flat li... |
ShareCafe | PAR | 1 year ago |
Paradigm Biopharmaceuticals (ASX:PAR) enters corporate partnership with NFL Alumni
Paradigm Biopharmaceuticals (PAR) enters into a corporate partnership with NFL Alumni Health The partnership will inform NFL Alumni members about osteoarthritis disease onset, current treatment options, and provide information about clinic... |
themarketherald.com.au | PAR | 1 year ago |
Why is the Paradigm share price surging 7% today?
The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is in the green on Wednesday following the companyâs latest announcement. At the time of writing, the biopharmaceutical companyâs shares are fetching at $1.055 each, up 0.48%... |
Motley Fool | PAR | 1 year ago |
Lunch Report: 13 July, 2022
ShareCafeLunch Report: 13 July, 2022 by Melissa Darmawan Australian stocks have lacked conviction today, shuffling above and below the flat line as investors weigh up the prospect of an aggressive rate hiking path to combat multi-year hig... |
ShareCafe | PAR | 1 year ago |